Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CTLA-4/PD-L1 Inhibitor
Davoceticept is a fusion protein consisting of the CD80 (1-107) fragment linked to IGHG1 Fc via a peptidyl linker, targeting CTLA-4 and PD-L1. This variant CD80 vIgD-Fc acts as an immune checkpoint inhibitor, enhancing T cell activation and promoting anti-tumor responses. Its applications include cancer immunotherapy and studying immune modulation in various malignancies, making it a valuable tool for researchers investigating therapeutic strategies in cancer treatment.
